Yuki N, Hayashi N, Mita E, Hagiwara H, Oshita M, Ohkawa K, Katayama K, Kasahara A, Fusamoto H, Kamada T
First Department of Medicine, Osaka University Medical School, Japan.
J Med Virol. 1995 Feb;45(2):162-7. doi: 10.1002/jmv.1890450209.
Genotyping of 179 consecutive Japanese chronic hepatitis C patients was carried out based on the variation in the hepatitis C virus (HCV) core gene. The results were correlated with clinical features and antibody responses toward specific HCV proteins deduced from the nucleotide sequence of genotype I/1a. Genotypes II/1b, III/2a, and IV/2b were identified in 138 (77%), 24 (13%), and 12 (7%) patients, respectively. Five patients had double infections. Genotype dependence was observed only for antibody response toward the NS4 (5-1-1) protein, which was infrequent in genotype III/2a patients (33%) compared with genotype II/1b (81%; P < 0.01) and genotype IV/2b (75%; P < 0.05). Following interferon-alpha therapy, sustained amniotransferase normalisation was achieved by 89% (eight of nine) patients without antibody to the 5-1-1 protein and 33% (17 of 51) with it (P < 0.01). These findings indicate that absence of antibody response to the 5-1-1 protein is frequent in genotype III/2a HCV carriers and may serve to predict responses to interferon therapy.
基于丙型肝炎病毒（HCV）核心基因的变异，对179例连续的日本慢性丙型肝炎患者进行了基因分型。结果与临床特征以及针对从基因I/1a核苷酸序列推导的特定HCV蛋白的抗体反应相关。分别在138例（77%）、24例（13%）和12例（7%）患者中鉴定出基因II/1b、III/2a和IV/2b。5例患者存在双重感染。仅在针对NS4（5-1-1）蛋白的抗体反应中观察到基因型依赖性，与基因II/1b患者（81%；P<0.01）和基因IV/2b患者（75%；P<0.05）相比，基因III/2a患者中这种情况不常见（33%）。在α干扰素治疗后，9例无5-1-1蛋白抗体的患者中有89%（8/9）实现了持续的转氨酶正常化，而有该抗体的51例患者中有33%（17/51）实现了持续的转氨酶正常化（P<0.01）。这些发现表明，在基因III/2a HCV携带者中，对5-1-1蛋白无抗体反应的情况很常见，并且可能有助于预测对干扰素治疗的反应。
